ArticleMolecules (Basel, Switzerland)2025
Design of Decanoic Acid/Polysorbate 80 Composite Vesicles as Cosmetics Carrier: Stability, Skin Permeability, Antioxidant and Antibacterial Activity.
Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of Bioactive Medium Chain Fatty Acids (CAntioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Fatty acid vesicles are natural biomaterials which possess unique bilayer structures and offer biomimetic advantages for drug and gene delivery. Nevertheless, the formation of fatty acid vesicles is limited to neutral alkaline circumstances and cannot adapt to the acidic environment of the living system. In this work, the non-ionic surfactant polysorbate 80 (TW80) was introduced, extending the pH window of vesicles formed by decanoic acid (DA) from 6.90-7.80 to 2.28-6.31. The DA/TW80 composite vesicles were used to encapsulate quercetin (QT), achieving an encapsulation efficiency of up to 75.6%. The formation of DA/TW80/QT composite vesicles was confirmed through Fourier transform infrared spectroscopy, differential scanning calorimetry, and X-ray diffraction. Moreover, free QT was released rapidly, while QT encapsulated in the DA/TW80 composite vesicles demonstrated a slower release profile. Skin permeability studies revealed that the cumulative drug penetration within 24 h using the DA/TW80/QT composite vesicles reached approximately 904.7 μg·cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.